Why Has Myriad (MYGN) Increased by 8.7% Since Last Earnings Report?
Myriad Genetics (MYGN) has seen an 8.7% increase in its stock since its last earnings report, outperforming the S&P 500 over the past month. Investors are now left wondering if this positive trend will continue leading up to the next earnings release or if Myriad is headed for a pullback.
In the third quarter of 2025, Myriad Genetics reported break-even earnings, surpassing the Zacks Consensus Estimate of a loss of 1 cent per share. The prior-year quarter had seen earnings of 6 cents per share. Adjusted earnings excluded amortization expenses, equity compensation, and real estate optimization, while GAAP net loss was 29 cents per share compared to a loss of 24 cents in the same quarter of the previous year.
Despite a 3.6% decrease in total revenues to $205.7 million year over year, Myriad Genetics managed to beat the Zacks Consensus Estimate by 0.24%. For the full year 2025, the company expects revenues in the range of $818-828 million, with adjusted earnings per share predicted to be between a loss of 2 cents and earnings of 2 cents. The Zacks Consensus Estimate for earnings in 2025 sits at 1 cent.
Since the earnings report, there has been a downward trend in fresh estimates, resulting in a -7.89% shift in the consensus estimate. Myriad holds a Growth Score of A and momentum score, a grade of C on the value side, placing it in the middle 20% for this investment strategy with an overall VGM Score of A.
Estimates for Myriad have generally been trending downward, showcasing a Zacks Rank #3 (Hold). Within the Zacks Medical – Biomedical and Genetics industry, Biogen Inc. (BIIB) experienced a 20.7% gain over the past month. In its most recent quarter, Biogen reported revenues of $2.53 billion, up 2.8% year over year, with EPS of $4.81 compared to $4.08 in the previous year.
For the current quarter, Biogen is projected to post earnings of $1.73 per share, a -49.7% change from the year-ago period. The Zacks Consensus Estimate saw a -14.1% change over the last 30 days, resulting in a Zacks Rank #3 (Hold) and a VGM Score of B for Biogen.
As for Myriad Genetics, while estimates have been on the decline, its Zacks Rank #3 (Hold) suggests an in-line return from the stock in the coming months.